Overview: Systemic Sclerosis IgG Profile Panel
Introduction: The Systemic Sclerosis IgG Profile Panel is a diagnostic tool designed for autoimmune disease screening using serum samples. In India, systemic sclerosis (SSc) affects ~10-20 per 100,000 population (higher female predominance), with diffuse form causing rapid skin tightening, lung fibrosis, and renal crisis, and limited form associated with Raynaud's and CREST features. High morbidity from under-testing in rural/low-SES patients with skin thickening, digital ulcers, or dyspnea, limited autoantibody labs, delayed immunosuppressive therapy leading to irreversible organ damage or pulmonary hypertension. Per rheumatology practices aligned with ICMR and Indian Rheumatology Association guidelines, the test employs immunoassay for 13 key autoantibodies (anti-Scl-70, anti-centromere, anti-Ro, anti-La, anti-Smith, anti-RNP, anti-Jo-1, anti-dsDNA, ANA, rheumatoid factor, anti-CCP, anti-U1RNP, anti-PM-Scl) over 3â€"5 days with high specificity, valuable for subtype classification, overlap syndrome detection, and prognosis (anti-Scl-70 linked to diffuse/lung risk, anti-centromere to limited/better prognosis). This diagnostic falls under autoimmune screening and targets patients with Raynaud's, sclerodactyly, or interstitial lung disease, addressing accurate detection to guide early immunosuppression, organ monitoring, and multidisciplinary care. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling comprehensive autoantibody profiling and reducing disability burden. Its serum-based approach ensures reliable multi-specificity assessment.
Other Names: Sys Scl IgG Pnl.
FDA Status: FDA approved, CLIA certified for immunology, compliant with 2025 standards.
Historical Milestone: Extended autoantibody profile standard in SSc classification; in India, expanding in rheumatology centers.
Purpose: The test assesses 13 parameters including anti-Scl-70 to guide systemic sclerosis screening, detect specific autoantibodies, inform subtype/prognosis.
Test Parameters: 1. Anti-Scl-70, 2. Anti-Centromere, 3. Anti-Ro, 4. Anti-La, 5. Anti-Smith, 6. Anti-RNP, 7. Anti-Jo-1, 8. Anti-dsDNA, 9. ANA, 10. Rheumatoid Factor, 11. Anti-CCP, 12. Anti-U1RNP, 13. Anti-PM-Scl.
Pretest Condition: No fasting required; patients should have Raynaud's or skin changes.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on skin tightening, Raynaud's, dyspnea.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected SSc including organ failure, benefits of screening, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 3â€"5 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive anti-Scl-70 indicates diffuse SSc with high lung risk; anti-centromere indicates limited form with better prognosis, necessitating specialist input.
Specialist Consultation: Rheumatologists should be consulted for management.
Additional Supporting Tests: Nailfold capillaroscopy, high-resolution CT chest, echocardiography for confirmation.
Test Limitations: Autoantibodies absent in some cases; comprehensive approach required.
References: Indian Journal of Rheumatology 2024, Scleroderma Studies India 2023.
